Add Formweb to your mobile device
Approved Formulary
Search results for:
cycloSPORINE PO
cycloSPORINE PO
Brand names: Neoral, SandIMMUNE
| Form | Strength |
|---|---|
| CAPSULE, ORAL | 25 mg; 100 mg; modified 25 mg; modified 100 mg |
| SOLUTION, ORAL | 100 mg/mL |
Medication comments:
| Per policy, these hazardous drugs have special waste requirements. | |
|---|---|
| Generic (Brand) | Waste Requirements |
| cycloSPORINE (SandIMMUNE) | Hazardous Waste ⇒ BLACK BUCKET |
| USP <800> Hazardous Drugs | ||||||
|---|---|---|---|---|---|---|
| Per Policy, these drugs have special handling requirements (any drug with an "AOR" is exempt from these requirements under normal circumstances). | ||||||
| generic (Brand) Route | Relative Risk Level | AOR? | NIOSH 2024 Table | MSHI?↑ | Warnings | |
| cycloSPORINE (SandIMMUNE, Gengraf, Neoral) IV | Highest | N/A | 1A↑ | No | IARC‑1↑ NTP‑1↑ | |
| NIOSH Supplemental information (2016): N/A FDA Pregancy Category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks; | ||||||
Last updated: Jun. 18, 2025
- Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug / Assessment of Risk
- Hazardous Waste BLACK BUCKET
- Black Box Warnings Infection, neoplasm, nephrotoxicity risk
- Look-Alike/Sound-Alike cycloSPORINE confused with cycloSERINE, cycloSPORINE modified